Simultaneous kissing drug-eluting stents to treat unprotected left main stem bifurcation disease: medium term outcome in 150 consecutive patients

2012 ◽  
Vol 8 (6) ◽  
pp. 691-700 ◽  
Author(s):  
Anjan Siotia ◽  
Allison C. Morton ◽  
Christopher J. Malkin ◽  
Tushar Raina ◽  
Julian Gunn
Keyword(s):  
Main Stem ◽  
Drug Eluting Stents ◽  
Left Main ◽  
Medium Term ◽  
Term Outcome ◽  
Left Main Stem ◽  
Drug Eluting

Stenting for Unprotected and Protected Left Main Stem Disease: A Comparison of Short- and Long-term Outcome

1997 ◽  
Vol 10 (6) ◽  
pp. 401-407
Author(s):  
FOUAD R. AMIN ◽  
PAUL A. KELLY ◽  
ARVINDER S. KURBAAN ◽  
JONATHAN R. CLAGUE ◽  
ULRICH SIGWART
Keyword(s):  
Main Stem ◽  
Left Main ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Left Main Stem ◽  
Short And Long Term ◽  
Left Main Stem Disease

scholarly journals Left Main Stem Percutaneous Coronary Intervention – Data and Ongoing Trials

2015 ◽  
Vol 10 (3) ◽  
pp. 132
Author(s):  
Rajiv Rampat ◽  
David Hildick-Smith ◽  
◽  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Complex Disease ◽  
Artery Bypass ◽  
Coronary Intervention ◽  
Current Data ◽  
Main Stem ◽  
Left Main ◽  
Left Main Stem ◽  
Percutaneous Coronary ◽  
Drug Eluting

Left main stem (LMS) disease is associated with significant morbidity and mortality. Traditionally coronary artery bypass grafting (CABG) has been the gold standard for treatment of these lesions. However over the past decade, percutaneous coronary intervention (PCI) has assumed a more prominent role in the treatment of LMS disease. With the advent of newer drug-eluting stents (DES) with an improved risk factor profile, better intravascular imaging modalities and careful patient selection, the use of PCI in this cohort is expanding. We review the current data to support this and discuss the on-going trials that will hopefully shed more light into the management of this complex disease.

Sign in / Sign up

Export Citation Format

Share Document